Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $53256.0.

  • Lipocine's Share-based Compensation fell 5064.04% to $53256.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $288998.0, marking a year-over-year decrease of 3756.83%. This contributed to the annual value of $409000.0 for FY2024, which is 3750.36% down from last year.
  • Latest data reveals that Lipocine reported Share-based Compensation of $53256.0 as of Q3 2025, which was down 5064.04% from $65205.0 recorded in Q2 2025.
  • Lipocine's Share-based Compensation's 5-year high stood at $178000.0 during Q1 2023, with a 5-year trough of $53256.0 in Q3 2025.
  • In the last 5 years, Lipocine's Share-based Compensation had a median value of $148000.0 in 2021 and averaged $131267.1.
  • Per our database at Business Quant, Lipocine's Share-based Compensation tumbled by 6839.1% in 2021 and then soared by 1785.71% in 2023.
  • Over the past 5 years, Lipocine's Share-based Compensation (Quarter) stood at $154689.0 in 2021, then grew by 6.76% to $165140.0 in 2022, then decreased by 7.09% to $153438.0 in 2023, then crashed by 35.13% to $99535.0 in 2024, then plummeted by 46.5% to $53256.0 in 2025.
  • Its last three reported values are $53256.0 in Q3 2025, $65205.0 for Q2 2025, and $71002.0 during Q1 2025.